预览加载中，请您耐心等待几秒...

美国ICPE规定的主药和辅料的管理——David-R.-Schoneker.ppt

预览
1/10
2/10
3/10
4/10
5/10
6/10
7/10
8/10
9/10
10/10

亲，该文档总共60页，到这已经超出免费预览范围，如果喜欢就直接下载吧～

下载提示 文本预览

如果您无法下载资料，请参考说明：

1、部分资料下载需要金币，请确保您的账户上有足够的金币

2、已购买过的文档，再次下载不重复扣费

3、资料包下载后请先用软件解压，在使用对应软件打开

IPECActivitiesandExcipientRegulationintheUnitedStatesOutlineWhatisIPEC?WhatisIPEC?Colorcon’sInvolvementwithIPECIPECMissionBuildingBridgeswithRegulatorsExcipientGMPsintheU.S.ExcipientGMPsintheU.S.IPECExcipientGMP’sIPECExcipientGMP’sPublishedIPEC-AmericasGuidelinesIPECInitiativesIPECInitiativesCurrentIPEAAuditReportsUseofExcipientsinNDA’sintheU.S.UseofExcipientsinNDA’sintheU.S.U.S.GenericApplicationsFDA’sInactiveIngredientDatabaseisavailableon-line: http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm Databasehascertainlimitations: Insomecases,aquantitativelimitisnotshowninthepublicversionduetoconfidentiality Oftenliststhesameexcipientbydifferentnamesandsometimesusestradenames(multiplelistingspossiblewithdifferentlevels) Theexactnameusedinthedatabasemustbeknowntosearch;acomprehensivelistcannotberetrieved DatabaseisonlyupdatedquarterlyGlobalCOLORANTRegulationsForPharmaceuticalsOneColorForTheWorld:GlobalFormulationProblemsKeyColorsUsedInGlobalPharmaceuticalsDesiredGlobalColorRegulationsDrugMasterFilesUSDMFFacts(J.Clark,FDA,2003)USDMFFilings,2002(J.Clark,FDA,2003)DrugMasterFileRequirementsTypeIVDMFInformationRequirementsIPECProposals:Global“ExcipientMasterFiles”ExcipientMasterFiles:ConsistentwithCTDSubmissionsExcipientMasterFileComponentsEMFOrganizationTheIncreasingVisibilityofExcipientsQualificationofExcipientSuppliersSupplierQualificationIPECExcipientQualificationGuidelineExcipientQualificationGuideline©Copyright–IPECAmericasExcipientQualificationProcess-User©Copyright–IPECAmericasPharmacopeialHarmonizationHarmonizationofExcipientStandardsToday’sHarmonizationOutcomesChinesePharmacopeiaProductFilingInformationPre-MixedExcipientsProductFilingInformationPre-mixedExcipientsDrugMasterFilesPre-mixedExcipientsPost-ApprovalChangesUnitedStatesTheSUPACGuidanceDefines:MajorImplicationsofSUPACIRQualityandPerformanceExcipientManufactureIPEC-SignificantChangeDefinedSignificantChangeExcipientManufacturingChangestoConsiderCriteriaforJudgingSignificanceLevelsofChange-SUPACTypeCon